Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
ALTANA Pharma |
---|---|
Information provided by: | ALTANA Pharma |
ClinicalTrials.gov Identifier: | NCT00546520 |
Ciclesonide is a novel inhaled corticosteroid for the treatment of asthma. In this study the effect of ciclesonide on airway hyperresponsiveness (AHR), exhaled nitric oxide (NO), and induced sputum inflammatory biomarkers will be evaluated.
Condition | Intervention | Phase |
---|---|---|
Asthma |
Drug: Ciclesonide |
Phase III |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Double Blind (Subject, Investigator), Placebo Control, Crossover Assignment, Safety/Efficacy Study |
Official Title: | A 3-Period Double-Blind, Cross-Over Study on the Onset of Action of Inhaled Ciclesonide (7 Days of 400 Mcg Sid Versus 800 Mcg Bid Versus Placebo) on Airway Responsiveness to Adenosine Monophosphate (AMP), Sputum Eosinophiles and Exhaled Breath Nitric Oxide (NO) in Patients With Asthma |
Enrollment: | 21 |
Study Start Date: | April 2002 |
Study Completion Date: | June 2002 |
Ages Eligible for Study: | 18 Years to 45 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Main inclusion criteria:
Main exclusion criteria:
Study ID Numbers: | BY9010/M1-125 |
Study First Received: | October 18, 2007 |
Last Updated: | December 10, 2008 |
ClinicalTrials.gov Identifier: | NCT00546520 |
Health Authority: | United Kingdom: Medicines and Healthcare Products Regulatory Agency |
Asthma Ciclesonide Airway hyperresponsiveness Sputum Nitric oxide |
Nitric Oxide Hypersensitivity Lung Diseases, Obstructive Respiratory Tract Diseases Ciclesonide |
Lung Diseases Hypersensitivity, Immediate Asthma Adenosine Respiratory Hypersensitivity |
Immune System Diseases Bronchial Diseases Therapeutic Uses Anti-Allergic Agents Pharmacologic Actions |